SCHEMBL22997743

SCHEMBL22997743

Cc1ccc(-n2cnc(-c3nc(N[C@H]4CCN(C(=O)OC(C)(C)C)C[C@H]4C)ncc3C(F)(F)F)c2)c(C#N)n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 2/20 0.40
▸ CCND1 P24385 2/20 0.40
▸ CCND3 P30281 2/20 0.40
▸ CDK6 Q00534 2/20 0.40
▸ GPR119 Q8TDV5 13/20 0.38
▸ USP30 Q70CQ3 1/20 0.37
▸ ALK Q9UM73 2/20 0.35
▸ CCNT1 O60563 1/20 0.35
▸ CDK1 P06493 1/20 0.35
▸ CCNB1 P14635 1/20 0.35
▸ CCNE1 P24864 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ CDK7 P50613 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ CCNH P51946 1/20 0.35
▸ MNAT1 P51948 1/20 0.35
▸ MAPK3 P27361 1/20 0.35
▸ SYK P43405 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29821604 1.00 CDK4 (0.40) CDK4CCND1CCND3CDK6GPR119
SCHEMBL22977436 0.92 CCNE1 (0.36) CDK4CCND1CCND3CDK6USP30
SCHEMBL22997830 0.81 CCNE1 (0.48) CDK4CCND1CCND3CDK6CCNT1
SCHEMBL22977445 0.81 CCNE1 (0.48) CDK4CCND1CCND3CDK6CCNT1
SCHEMBL22977076 0.81 CCNE1 (0.39) CDK4CCND1CCND3CDK6CCNT1
SCHEMBL22997651 0.81 CCNK (0.43) CDK4CCND1CCND3CDK6CCNT1
SCHEMBL30449674 0.81 CCNK (0.43) CDK4CCND1CCND3CDK6CCNT1
SCHEMBL22977410 0.81 CCNK (0.43) CDK4CCND1CCND3CDK6CCNT1
Hydrochloric Acid SCHEMBL22977438 0.80 CCNK (0.43) CDK4CCND1CCND3CDK6CCNT1
Hydrochloric Acid SCHEMBL30449694 0.80 CCNK (0.43) CDK4CCND1CCND3CDK6CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116348458-A Imidazolylpyrimidinylamine compounds as CDK2 inhibitors 因赛特公司 2023-06-27 — — CN disclosed
US-20230024173-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2023-01-26 — — US disclosed
WO-2021030537-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION (US) 2021-02-18 — — WO disclosed
US-20210047294-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2021-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210047294-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 CDK4 2/4885CCND1 54/4885CCND3 59/4885
US-20230024173-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 CDK4 2/4885CCND1 54/4885CCND3 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback